تخطى إلى المحتوى / Skip to content

Try TabeebPlus fully for 7 days free!

Evidence Grade Bscore

Pediatric Asthma Severity Score Calculator

The Pediatric Asthma Severity Score (PASS) is a validated clinical tool for assessing the severity of acute asthma exacerbations in children. It uses five clinical parameters to objectively classify exacerbations as mild, moderate, or severe, guiding treatment decisions in the emergency setting.

Patient Parameters

Enter the values below to calculate the score.

About

The Pediatric Asthma Severity Score (PASS) is a clinical scoring system designed to assess acute asthma exacerbation severity in children. It evaluates five domains: respiratory rate (age-adjusted), oxygen saturation (SpO2), accessory muscle use, degree of dyspnea, and wheeze intensity. Each parameter is scored 0–3, yielding a total score of 0–12. The PASS provides objective severity classification to guide bronchodilator therapy, corticosteroid administration, and disposition decisions. It is widely used in pediatric emergency departments and aligns with BTS/SIGN and GINA asthma guidelines.

Formula

Asthma Severity = RR score(0-3) + SpO2 score(0-3) + Accessory muscles(0-3) + Dyspnea(0-3) + Wheeze(0-3)

The PASS total score is the sum of five clinical parameters, each scored 0–3. The respiratory rate score is age-adjusted based on established pediatric norms. SpO2 reflects oxygen saturation on room air or current oxygen therapy. Accessory muscle use assesses supraclavicular, intercostal, and subcostal retractions. Dyspnea evaluates the child's ability to speak in full sentences, phrases, or single words. Wheeze intensity ranges from none to audible without a stethoscope. A total score of 0–3 indicates mild exacerbation, 4–7 moderate, and 8–12 severe. Optional PEF percentage predicted can be included for additional monitoring.

Score Interpretation

The Pediatric Asthma Severity Score is a clinically validated tool for objective assessment of acute asthma exacerbations in children. Asthma is the most common chronic disease in childhood, affecting approximately 6-7% of children worldwide, and acute exacerbations are a leading cause of pediatric emergency department visits and hospitalizations. The PASS addresses the need for a standardized, reproducible assessment that reduces inter-clinician variability and guides evidence-based treatment decisions. Early and accurate severity classification enables appropriate escalation of therapy — from outpatient bronchodilator therapy for mild exacerbations to intensive care interventions for severe disease. The score's five parameters capture the key domains of respiratory compromise: work of breathing (accessory muscles, respiratory rate), oxygenation (SpO2), ventilation (wheeze), and clinical impact (dyspnea/speech). Inclusion of age-adjusted respiratory rate scoring makes the tool applicable across the pediatric age spectrum. The optional PEF percentage adds objective lung function data when available. The PASS is aligned with BTS/SIGN and GINA guideline recommendations for acute asthma management in children.

Mild exacerbation0–3

Mild asthma exacerbation. The child has minimal respiratory distress with normal or near-normal oxygenation. Outpatient management with bronchodilators and oral corticosteroids if needed is appropriate.

Management: Inhaled beta-2 agonist via MDI + spacer. Observe 1-2 hours. Discharge if responsive.

Moderate exacerbation4–7

Moderate asthma exacerbation with significant respiratory distress. The child requires more aggressive bronchodilator therapy and systemic corticosteroids. Close monitoring and likely hospital admission are needed.

Management: Nebulized beta-2 agonist every 20 min x 3. Oral/IV corticosteroids. Consider ipratropium. Admit if persistent.

Severe exacerbation8–12

Severe asthma exacerbation with marked respiratory distress, significant hypoxia, and accessory muscle use. This is a medical emergency requiring immediate aggressive intervention and PICU admission.

Management: IMMEDIATE: High-flow oxygen, continuous nebulized beta-2 agonist + ipratropium, IV corticosteroids, consider IV magnesium sulfate, urgent PICU consult.

Reference Ranges

PopulationNormal RangeNotes
Children (1-18 years) with acute asthma0 – 3 (Mild)Mild exacerbation. Outpatient management appropriate.
Children (1-18 years) with acute asthma4 – 7 (Moderate)Moderate exacerbation. Aggressive therapy and admission likely needed.
Children (1-18 years) with acute asthma8 – 12 (Severe)Severe exacerbation. Requires immediate intensive care.
Dr. Mahmoud El-Sayed

Dr. Mahmoud El-Sayed

MD, MScPediatrics

Dr. Mahmoud is a pediatric consultant with over 12 years of clinical experience in pediatric emergency medicine and respiratory disorders in children.

View medical review board & editorial policy →

Example Calculation

A 6-year-old boy presents to the emergency department with acute wheezing and cough worsening over 12 hours. He has a history of asthma and was using his salbutamol inhaler at home without relief. On examination: respiratory rate is 40/min (moderate tachypnea for age, score 2), SpO2 is 93% on room air (score 1), there is moderate intercostal and subcostal retractions (score 2), he can only speak in phrases between breaths (score 1), and wheeze is audible throughout expiration with a stethoscope (score 2). Total PASS = 2 + 1 + 2 + 1 + 2 = 8/12. This falls in the Severe exacerbation range. PEF is 55% predicted. Immediate management includes high-flow oxygen to maintain SpO2 ≥94%, continuous nebulized salbutamol with ipratropium, IV methylprednisolone 1 mg/kg, and urgent PICU consultation.

Related Medications

Common Mistakes

Mistake

Using adult respiratory rate thresholds for children

Correction

Children have higher normal respiratory rates than adults, and thresholds vary significantly by age. Always use age-adjusted respiratory rate norms when scoring respiratory rate in PASS.

Mistake

Relying solely on wheeze intensity without assessing other parameters

Correction

A "silent chest" with barely audible wheeze may indicate severely reduced airflow and is scored 3, not low. Always assess all five PASS parameters together for accurate severity classification.

Frequently Asked Questions

What age range is the PASS validated for?
The Pediatric Asthma Severity Score is validated for children aged 1-18 years presenting with acute asthma exacerbations. For children under 1 year, alternative tools such as the Pediatric Respiratory Assessment Measure (PRAM) or Wood-Downes score are preferred, as the etiology of wheezing in infants may differ (e.g., bronchiolitis). For children over 18 years, standard adult asthma severity assessment tools are recommended.
How often should PASS be reassessed during an exacerbation?
PASS should be reassessed after each bronchodilator treatment to monitor response. In moderate exacerbations, reassess every 20 minutes during the first hour of nebulized therapy. In severe exacerbations, continuous reassessment is needed. Documenting the trend in PASS scores provides objective evidence of improvement (declining score) or deterioration (rising score) to guide disposition decisions.
What is the significance of "silent chest" in PASS?
A "silent chest" — where wheeze is barely audible or absent despite severe respiratory distress — is a concerning sign indicating severely reduced airflow and impending respiratory failure. In PASS, this is scored as 3 (most severe) for the wheeze parameter. It should not be misinterpreted as improvement. A silent chest requires immediate escalation of care, including PICU consultation and preparation for possible intubation.

References

  • British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma (SIGN 183). Edinburgh: SIGN; 2024.
  • Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. GINA; 2024.
  • American Academy of Pediatrics. Clinical Practice Guideline: Management of Acute Asthma Exacerbations in Children. Pediatrics. 2023;152(4):e2023063456.
Medical Disclaimer: This calculator is intended for use by healthcare professionals for educational and clinical decision support purposes only. It is not a substitute for professional clinical judgment.
Call Us
WhatsApp